semaglutide fda weight loss What's New in Obesity Treatment? The FDA's Decision to Ban

Base biz revenue grew a solid 22.4 per cent YoY, while Ebitda margin zoomed up 193bps YoY to a record 40.2 per cent

Semaglutide stimulates insulin production and lowers blood-sugar levels, mimicking glucagon-like peptide-1, a hormone that signals fullness and slows gastric emptying

By virtue of their peptide character, the peptidomimetic inhibitors have poor pharmacokinetics due to susceptibility to metabolic cleavage by peptidases

Two GLP-1s are FDA-approved for long-term weight management: the once-weekly Wegovy and the daily-dose Saxenda (liraglutide)

As a weight loss medication, these GLP-1 injections lower body mass index (BMI) and increase metabolism, allowing your body to burn more fat and support proper weight loss

This biological support creates an opportunity to reshape your relationship with food and exercise, making it easier to implement important dietary changes